



# Precision Oncology Workshop: From Genomics to Therapeutics

---

**Saturday 14th February 2026**

9.00am - 5.00pm

Intercontinental, Brisbane

Brisbane, QLD

AUSTRALIA



Premium Plus sponsor: **illumina**<sup>®</sup>

# FOREWORD



Dear Colleagues and Partners,

It is with great enthusiasm that we welcome you to the 2026 Precision Oncology Workshop, at the Intercontinental Hotel in Brisbane on Saturday 14<sup>th</sup> February.

As precision medicine continues to transform the landscape of cancer care, this workshop will bring together leading clinicians and experts, emerging leaders, researchers, and industry partners to accelerate innovation and improve patient outcomes across Australia.

Your attendance will be instrumental in empowering the oncology community to share the latest advances in molecular diagnostics, targeted therapies, genomics, pharmacogenomics and patient-centered care.

Together, we will create an environment for knowledge exchange, practical collaboration, and the translation of cutting-edge science into everyday practice.

By joining us, you are not only demonstrating your commitment to excellence in cancer treatment, but also helping to shape the future of oncology for patients and clinicians alike.

We look forward to working with you, in making the 2026 Precision Oncology Workshop a continued landmark event and a catalyst for progress in personalised cancer care.

Warm regards,

A handwritten signature in black ink, appearing to read 'Chris Steer'.

A/Professor Christopher Steer  
President, Private Cancer Physicians of Australia

**illumina**<sup>®</sup>

abbvie



**GSK**



**A. MENARINI**  
Pharma

**ThermoFisher**  
SCIENTIFIC

# AGENDA



**SATURDAY 14 February 2026**

Ballroom A&B, InterContinental Hotel, Brisbane

Time	Topic	Speaker
8.55am	<i>Opening Remarks</i>	<i>Dr Adam Boyce</i>
9.00am	<b>A Refresher on Fundamentals of Clinical Molecular Pathology</b>	<i>Dr Vivek Rathi &amp; Dr Lynn Fink</i>
	Types of genetic alterations and their relevance in oncology Matching tumour type to the most appropriate molecular test Ingredients of a molecular (NGS) report Update on Medicare rebate for molecular testing of solid tumours	
10.45am	Break	
11.00am	<b>Genetic Counselling for Cancer Patients</b>	<i>Amy Pearn</i>
11.30am	<b>ESR1 Testing in Breast Cancer</b>	<i>Professor Anthony Gill</i>
12.00pm	<b>Tumour Informed MRD and Methylation Profiling – Current and Emerging Applications</b>	<i>Dr Joel Geoghegan</i>
12.25pm	Lunch	
1.00pm	<b>Liquid Biopsy in Lung Cancer Patient Management</b>	<i>Assoc Professor Mal Itchins</i>
1.30pm	<b>Liquid Biopsy in Colorectal Cancer Patient Management</b>	<i>Professor Lorraine Chantrill</i>
2.00pm	<b>Crucial Role of Molecular Tumour Board in Cancer Patient Management</b>	<i>Dr Vivek Rathi</i>
2.30pm	Afternoon Tea	
3.00pm	<b>Integrating Genomic Data into Oncology Practice, Opportunities and Challenges</b>	<i>Dr Gregory Gaughran</i>
3.35pm	<b>Increasing Significance of Pharmacogenomics (DPYD) Testing in Oncology</b>	<i>Dr Sam Mostafa</i>
4.00pm	<b>Expert Panel case studies, Q&amp;A</b>	<i>Presenters &amp; Dr Cath Shannon</i>
4.55pm	<i>Close</i>	<i>Dr Adam Boyce</i>

illumina®

abbvie



GSK



A. MENARINI  
Pharma

ThermoFisher  
SCIENTIFIC

# SPEAKER BIOS



## Dr Adam Boyce

Dr Adam Boyce is a Medical Oncologist with over 20 years of clinical experience, renowned for both his expertise and compassionate approach to patient care across public and private sectors in the Northern Rivers, NSW. He is head of the Medical Oncology Unit at Lismore Base Hospital and St Vincent's Private Hospital, Lismore, and is actively involved in clinical research as principal investigator on numerous trials. Dr Boyce manages all solid tumour types, with special interests in breast, lung, melanoma/skin, gastrointestinal, and genitourinary cancers. He is deeply committed to improving rural equity in cancer care and advancing medical education, contributing to organizations like PCPA and COSA, and was instrumental in founding Lismore's comprehensive cancer centre over 20 years ago and Our House patient accommodation charity.



## Professor Lorraine Chantrill

Prof Lorraine Chantrill is a Senior Staff Specialist Medical Oncologist and Medical Co-Director for Medical Oncology across the Illawarra Shoalhaven Local Health District (ISLHD) and Director of Clinical Trials.

Lorraine is keen to build the region's clinical trial portfolio to give patients access to some new and emerging therapies.

GI Cancer Trials create and facilitate clinical trials in cancers of the digestive tract. She was appointed to the Board of Directors of AGITG in August 2016 and in May 2020 became the first female Chair of the AGITG and GI cancer institute.



## Dr Lynn Fink (BSc, PhD, FFSc RCPA [Pathology Informatics])

Laboratory Director, LifeStrands Genomics Australia

Senior clinical scientist specializing in clinical bioinformatics, with a fellowship from the Faculty of Sciences of the Royal College of Pathologists of Australasia.

Bachelor of Science from The University of Arizona (1995) and PhD from The University of California, San Diego (2003), focusing on Biomedical Sciences. Postdoctoral work at the University of Queensland, collaborating with international consortia like the RIKEN FANTOM3 project and the International Cancer Genome Consortium. Over 80 peer-reviewed publications and numerous presentations on precision diagnostics and medicine.



# SPEAKER BIOS (CONT)



## Dr Gregory Gaughran

Greg is a medical oncologist based in Melbourne, Australia, with specialty interests in gastrointestinal (GI), head and neck (HNSCC), and breast cancers. He holds clinical appointments at Geelong and Box Hill hospitals and maintains active research roles in genomics and precision oncology with Monash University, Alfred Health, and the University of New South Wales. Dr Gaughran also works as a cancer genomicist at OMICO/CASP and is involved in several molecular tumor boards. Additionally, he is completing a clinical fellowship in cancer genetics at Monash Health and is an MPH candidate focusing on biostatistics and genomics. He regularly contributes as a medical writer and serves on national committees such as COSA's Geriatric Oncology Research Committee and the Victorian HNSCC Summit Committee..



## Dr Joel Geoghegan

Illumina Business Unit Manager, Oncology for Africa, Middle East and Asia. As BU Manager for Oncology with Illumina, Joel Geoghegan is responsible for driving Illumina's oncology strategy for Africa, the Middle East and Asia. He is focused on enabling precision medicine at scale to maximise improvement in outcomes for cancer patients. This includes expanding access to next-generation sequencing technology to aid in the diagnosis, prognosis, therapy selection and monitoring of patients.

Joel has over 25 years of experience working in the genomics industry. This includes research fellowships at the National Cancer Institute, R & D positions within the biotech industry, and running a genomics facility within a pathology setting. Focus and expertise on new technologies has led to numerous collaborations with key opinion leaders around the world resulting in publications in Nature Genetics, Nature Methods, PNAS, Human Mutation, Blood and Leukaemia.

illumina®

abbvie



GSK



A. MENARINI  
Pharma

ThermoFisher  
SCIENTIFIC

# SPEAKER BIOS (CONT)



## Professor Anthony Gill AM

Anthony is Professor of Surgical and a senior staff specialist in anatomical pathology at the Royal North Shore Hospital in Sydney. He graduated from the University of Sydney in 1997, and after three years in internal and emergency medicine he subspecialized in anatomical Pathology. He has co-authored over 500 highly cited original research publications in addition to numerous invited review articles and book chapters. He is chairman of the Australian Pancreatic Genome Initiative (APGI) and a standing editorial board member for the fifth edition series of the World Health Organization / International Agency for Research on Cancer (WHO/IARC) classification of tumours. He has a particular interest in the surgical pathology of endocrine and hereditary tumours. In 2018 he was appointed a member of the order of Australia (AM) in the Queens Birthday honours list “for significant service to medical research in the field of surgical pathology as an academic, author; adviser, and mentor”.



## Associate Professor Malinda Itchins

Dr Malinda Itchins (BMedSci; MBBS(Hons); FRACP; PhD) is a Thoracic Medical Oncologist at Royal North Shore Hospital and Chris O'Brien Lifehouse. She is a Board Director with the Clinical Oncology Society of Australia (COSA); and Co-Chair of the Advanced NSCLC Scientific Committee with Thoracic Oncology Group of Australasia (TOGA) and her research interests include precision therapeutics and drug resistance in lung cancer.



## Dr Sam Mostafa

Dr. Sam Mostafa, PhD, BPharm, is the Clinical Director at myDNA, where he oversees the delivery of specialised clinical pharmacogenomic services. With an international footprint spanning Australia, Europe and the USA, Sam specialises in the translational implementation of genomic data into routine clinical care. He is a key contributor to national policy as a member of the RCPA Advisory Committee for pharmacogenomic indications. Committed to advancing the field through education, Sam holds academic appointments at Monash University and the University of Sydney, where he supervises PhD-level translational research.



# SPEAKER BIOS (CONT)



## Amy Pearn

Amy is a cancer genetic counsellor trained at the University of Newcastle, and certified by both the Human Genetics Society of Australasia (HGSA) and the Canadian Board of Genetic Counsellors (CBGC). Amy founded The Gene Council, a private virtual cancer genetic counselling and testing service based in Perth. She sat on the eviQ Cancer Genetics Reference Committee for over 10 years, coordinated the roll-out of mainstream genetic testing for women with ovarian cancer in WA, and works with the HGSA as a Project Officer for the ongoing development of resources to support mainstream genetic testing in cancer care.



## Dr Vivek Rathi

Medical Director, LifeStrands Genomics Australia

Molecular and Anatomical Pathologist with Fellowship of The Royal College of Pathologists of Australasia.

Specialises in all aspects of cancer genomics, including clinical supervision, genomic testing, assay development, and data curation.

Former Department Director of Diagnostic Genomics at Monash Health and Staff Specialist at St Vincent's Hospital Melbourne.

Instrumental in establishing genomic services for precision oncology at multiple sites, developed protocols that significantly improve the accuracy and efficiency of genomic testing, directly benefiting patient care.



## Dr Cath Shannon

Dr Catherine Shannon is Senior Medical Oncologist at Mater Cancer Care Centre, a member of Mater Research's Clinical Research group and Senior Lecturer University of Queensland. She is the principal or co-investigator on a number of phase I, II and III clinical trials in breast, gynaecological and lung cancer. She is currently on the Executive Committee of the Medical Oncology Group of Australia and the medical oncology consultant for the National Breast and Ovarian Cancer Centre.

Dr Shannon completed a fellowship with Breast Cancer Unit of the Royal Marsden Hospital where she researched pre-operative endocrine therapy of breast cancer and the use of biological markers as predictors of response to treatment. She obtained extensive experience in phase I and II trials of novel agents for metastatic breast cancer. Her research publications include the molecular genetics of synchronous gynaecological tumours and neoadjuvant therapies for breast cancer. Dr Shannon chaired the committee in writing endocrine therapy guidelines for the management of advanced breast cancer.

Dr Shannon has a special interest in the management of breast cancer in young women and pregnant women and has published in this field.

# SPONSORS



We welcome our valued members and industry partners.

Premium Plus Sponsor

---



Premium Sponsor

---



**A. MENARINI**  
*Pharma*



abbvie

AstraZeneca 

GSK

 LifeStrands  
Empowering lives with Genomics

 MSD

 NOVARTIS

 Roche

 maurice  
blackburn  
lawyers

Partners

---

Fletcher || Clarendon

  
SCIENCETOLIFE

# PCPA EXECUTIVES AND BOARD



## **President**

A/Professor Christopher Steer  
Medical Oncologist,  
Albury Wodonga Regional  
Cancer Centre



## **Treasurer**

Professor Desmond Yip  
Medical Oncologist  
The Canberra Hospital & National  
Capital Medical Specialists



## **QLD State Director**

Dr Ian Irving  
Clinical Haematologist,  
Icon Group Medical Director



## **Secretary & Chair of Education**

Prof Stephen Clarke OAM  
Medical Oncologist,  
Sydney University



## **VIC State Director**

Dr Cameron McLaren  
Medical Oncologist,  
St John of God, Berwick & Bendigo



## **NSW/ACT State Director**

Dr Anupriya Agarwal  
Medical Oncologist  
Prince of Wales Private & Mater  
Hospital



## **Emerging Leaders Director**

Dr Amy Davies  
Medical Oncologist  
Epworth Freemasons & SJO Bendigo



## **WA State Director**

Dr Arman Hasani,  
Medical Oncologist,  
Joondalup Private Hospital



## **TAS State Director**

Dr Sunit Sarkar  
Medical Oncologist,  
Icon Cancer Centre,  
Hobart, Royal Hobart Hospital



## **SA/NT State Director**

Dr Tony Michele  
Medical Oncologist,  
North Adelaide Oncology



## **Rural Representative**

Dr Adam Boyce  
Medical Oncologist,  
St Vincents Lismore



## **Radiation Oncology Director**

Dr Evan Ng  
Radiation Oncologist  
Fiona Stanley Hospital



## **Haematology Director**

Assoc Professor Costas Yannakou  
Clinical Haematologist  
Epworth HealthCare





## Contact:

Jennifer Burgess, PCPA Secretariat

Ph: (07) 3872 2234 | M: 0411 052 722

E: [j.burgess@amaq.com.au](mailto:j.burgess@amaq.com.au)

W: [www.pcpa.org.au](http://www.pcpa.org.au)



**Together  Stronger**  
*Futureproofing cancer care*